Selected publications
-
Genomic characteristics of trastuzumab-resistant Her2-positive metastatic breast cancer.
Journal of Cancer Research and Clinical Oncology.
2017
Academic Article
GET IT
Times cited: 7 -
Hyperactivated mTOR and JAK2/STAT3 Pathways: Molecular Drivers and Potential Therapeutic Targets of Inflammatory and Invasive Ductal Breast Cancers after Neoadjuvant Chemotherapy.
Clinical Breast Cancer.
2016
Academic Article
GET IT
Times cited: 22 -
Recommendations on disease management for patients with advanced human epidermal growth factor receptor 2-positive breast cancer and brain metastases: American Society of Clinical Oncology clinical practice guideline.
Journal of Clinical Oncology.
2014
Review
GET IT
Times cited: 103 -
Systemic therapy for patients with advanced human epidermal growth factor receptor 2-positive breast cancer: American Society of Clinical Oncology clinical practice guideline.
Journal of Clinical Oncology.
2014
Review
GET IT
Times cited: 219 -
Biomarker-guided sequential targeted therapies to overcome therapy resistance in rapidly evolving highly aggressive mammary tumors.
Cell Research.
2014
Academic Article
GET IT
Times cited: 18 -
Genome-based risk prediction for early stage breast cancer.
Oncologist.
2014
Review
GET IT
Times cited: 6 -
Pertuzumab in the treatment of HER2+ breast cancer.
JNCCN Journal of the National Comprehensive Cancer Network.
2014
Review
GET IT
Times cited: 15 -
Serum HER-2/neu and relative resistance to trastuzumab-based therapy in patients with metastatic breast cancer.
Cancer.
2008
Academic Article
GET IT
Times cited: 76 -
Clinical utility of serum HER2/neu in monitoring and prediction of progression-free survival in metastatic breast cancer patients treated with trastuzumab-based therapies.
Breast Cancer Research.
2005
Academic Article
GET IT
Times cited: 120 -
Pharmacoproteomic Analysis of Prechemotherapy and Postchemotherapy Plasma Samples from Patients Receiving Neoadjuvant or Adjuvant Chemotherapy for Breast Carcinoma.
Cancer.
2004
Academic Article
GET IT
Times cited: 91 -
Weekly trastuzumab and paclitaxel therapy for metastatic breast cancer with analysis of efficacy by HER2 immunophenotype and gene amplification.
Journal of Clinical Oncology.
2001
Academic Article
GET IT
Times cited: 523